“All for One,One for All”: Evaluating Composite Endpoints in Clinical Trials

Abstract

Get full access to this article

View all access options for this article.

References

Montori

Permanyer-Miralda

Ferreira-Gonzalez

. Validity of composite end points in clinical trials. BMJ 2005;330:594–6.

Schulz

Grimes

. Multiplicity in randomized trials I: endpoints and treatments. Lancet 2005;365:1591–5.

Cook

Gebski

Keech

. Subgroup analysis in clinical trials. Med J Aust 2004;180:289–91.

Freemantle

Calvert

Wood

. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554–9.

Yusuf

Pfeffer

Swedberg

. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81.

Niewoehner

Erbland

Deupree

. Effect of systematic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941–7.

Crowther

Hiller

Moss

. Australian Carbohydrate Intolerance Study in Pregnant Women (AHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477–86.

Lewis

Hunsicker

Clarke

. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.

Courtney

Farrell

Gray

. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–15.

10.

Montori

Busse

Permanyer-Miralda

. How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump? ACP J Club 2005;143:A8.